Lupin faces GST inspection in Maharashtra; says no impression on funds, enterprise actions

Pharma main Lupin Ltd. on Wednesday stated the Maharashtra Items and Providers Tax (GST) Division has initiated an inspection and search at one in every of its places of work, in search of paperwork associated to GST funds and enter tax credit score claims.

In a regulatory submitting, the corporate clarified that it’s totally cooperating with authorities and that the continued proceedings haven’t any impression on its financials, operations or enterprise actions. The inspection is targeted on documentation and compliance features linked to GST remittances and credit score claims.

Regardless of the event, Lupin’s shares closed marginally larger at ₹2,293 apiece, gaining 1.90% for the day, suggesting restricted investor concern over the regulatory motion.

Enterprise developments

The replace comes amid a collection of optimistic enterprise developments for the drugmaker. Earlier this week, Lupin introduced that it has obtained approval from the European Fee for its biosimilar Ranluspec (ranibizumab), following a optimistic opinion from the Committee for Medicinal Merchandise for Human Use.

Ranibizumab is indicated for the remedy of a number of retinal issues, together with neovascular (moist) age-related macular degeneration, diabetic macular edema, proliferative diabetic retinopathy, macular edema following retinal vein occlusion and choroidal neovascularization.

Lupin’s biosimilar can be commercialised by Sandoz throughout the European Union, excluding Germany. In France, the product can be marketed by each Sandoz and Biogaran.

In a separate announcement, the corporate stated it has launched Brivaracetam Oral Resolution (10 mg/mL) in the USA after receiving approval from the US Meals and Drug Administration. The anti-seizure remedy provides to Lupin’s rising portfolio within the US market.

Q3 outcomes

Robust US efficiency helped drive earnings within the quarter ended December 31, 2025. Lupin reported a consolidated internet revenue of ₹1,175.6 crore, up 37.5% year-on-year. Consolidated income from operations stood at ₹7,167.5 crore, rising 1.7% quarter-on-quarter and 24.3% year-on-year.

Gross revenue for Q3 FY26 got here in at ₹5,222.4 crore, with a gross margin of 73.5%. The US continued to be Lupin’s largest market, accounting for 44% of worldwide gross sales at ₹3,113.2 crore throughout the quarter.

India gross sales rose 5.6% year-on-year to ₹2,038.7 crore, contributing 29% of worldwide revenues. Lupin launched three new manufacturers throughout therapies throughout the quarter and ranked because the eighth-largest firm within the Indian Pharmaceutical Market, in line with IQVIA MAT December 2025 knowledge.

“We’re blissful to ship one other quarter of robust progress led by our highest-ever quarterly gross sales within the US and double-digit progress in India and all different areas. We’re on observe to ship a robust near FY26,” stated Nilesh Gupta, Managing Director, Lupin Restricted.

The corporate invested ₹535.2 crore in analysis and growth throughout the quarter, representing 7.5% of gross sales, underscoring its continued give attention to pipeline enlargement and biosimilar progress.